Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL11031577 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL8472459 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL7927609 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL26606265 | 1.00 | LMNA (0.69) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Xylitol SCHEMBL7891509 | 0.94 | LMNA (0.59) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Ribitol SCHEMBL4415333 | 0.94 | LMNA (0.59) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL28100683 | 0.92 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Sorbitol SCHEMBL29359900 | 0.91 | LMNA (0.65) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Mannitol SCHEMBL21903806 | 0.91 | LMNA (0.65) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Sorbitol SCHEMBL29493079 | 0.91 | LMNA (0.65) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | claimed |
| EP-2178855-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010554-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-22 | — | — | WO | claimed |
| EP-2017273-A1 | Process for the enantioselective preparation of pregabalin | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | claimed |
| CN-101848905-A | Process for the enantioselective preparation of pregabalin | ESTEVE LABOR DR | 2010-09-29 | — | — | CN | disclosed |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| EP-2178855-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010554-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-22 | — | — | WO | disclosed |
| EP-2017273-A1 | Process for the enantioselective preparation of pregabalin | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | GABRE, CYP2D6, GABRG2 | LMNA 2035/4885L3MBTL1 4880/4885TDP1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.